13F Holdings
中文EN

SER Serina Therapeutics, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1708599 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY132.1%
TTM net income YoY-72.2%
TTM EPS YoY-26.5%
Revenue 3-yr CAGR56.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-18,478.5%
Net margin-14,755.4%
FCF margin-13,856.9%
EBITDA margin-18,439.2%

Returns

ROE-6,351.7%
ROA-280.5%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets100.5%
Debt / equity—
Current ratio1.71x
Interest coverage-112.78x

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-17.9%
Payout ratio—
Capex / revenue45.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$130,000$56,000$3.15M$34,000$144,000
Cost of revenue——$40,000$13,000$19,000
Gross profit——$102,000$21,000$125,000
R&D expense$13.15M$7.48M$2.39M$1.02M$1.46M
SG&A expense$11.00M$9.62M$3.89M$5.97M$6.71M
Operating income-$24.02M-$17.05M-$3.13M-$6.97M-$7.93M
Interest expense$213,000$526,000$558,000$3.33M$1.10M
Pretax income-$19.20M-$11.21M$5.27M$10.50M$8.70M
Income tax$18,000$0$0——
Net income-$19.18M-$11.14M$5.27M-$10.46M-$8.68M
EBITDA-$23.92M-$16.95M-$3.04M——
EPS (basic)-1.91-1.512.36-9.70-0.23
EPS (diluted)-1.91-1.510.73-9.70-0.23
Weighted avg. shares (diluted)10.19M7.36M7.35M1,07937.89M
Balance sheet
Cash & equivalents$3.06M$3.67M$7.62M$645,000$584,000
Receivables——$57,000$4,000$25,000
Current assets$6.08M$5.68M$7.62M$2.45M$2.23M
PP&E, net$465,000$501,000$573,000——
Intangibles——$0$738,000$870,000
Total assets$6.95M$6.72M$8.97M$3.24M$3.15M
Current liabilities$3.56M$2.37M$1.41M$10.08M$8.97M
Long-term debt———$18.12M$13.20M
Total debt———$18.12M$13.20M
Total liabilities$6.99M$6.22M$4.86M$20.56M$15.03M
Shareholders' equity-$37,000$641,000-$32.29M-$37.78M-$11.83M
Net debt———$17.48M$12.62M
Shares outstanding10.77M9.42M2.41M1.08M37.94M
Cash flow statement
Operating cash flow-$17.95M-$17.14M-$2.48M-$5.94M-$7.86M
Capital expenditure$59,000$22,000$504,000——
Free cash flow-$18.01M-$17.16M-$2.98M——
Investing cash flow-$59,000-$22,000-$504,000—$666,000
Financing cash flow$17.41M$13.21M$10.07M$6.00M$7.25M
Depreciation & amortization$100,000$100,000$90,000——
Stock-based compensation$3.79M$2.60M$25,000$760,000$999,000

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.